- ICH GCP
- Rejestr badań klinicznych w USA
- Badanie kliniczne NCT00260208
Liver Fibrosis in Patients Transplanted for Hepatitis C Receiving Either Cyclosporine Microemulsion or Tacrolimus
A Multicenter, Randomized, Open-label Study to Compare the Development of Liver Fibrosis at 12 Months After Transplantation for Hepatitis C Cirrhosis in Patients Receiving Either Cyclosporine Microemulsion or Tacrolimus
Przegląd badań
Status
Interwencja / Leczenie
Typ studiów
Zapisy (Rzeczywisty)
Faza
- Faza 4
Kontakty i lokalizacje
Lokalizacje studiów
-
-
New Jersey
-
East Hanover, New Jersey, Stany Zjednoczone
- Novartis Investigative Site
-
-
-
-
-
Zurich, Szwajcaria, 8091
- Novartis Investigational site
-
-
Kryteria uczestnictwa
Kryteria kwalifikacji
Wiek uprawniający do nauki
Akceptuje zdrowych ochotników
Płeć kwalifikująca się do nauki
Opis
Inclusion criteria
- Reason for transplant is end-stage liver disease due to hepatitis C cirrhosis
- Patients receiving a first liver transplant from a deceased or living donor
- Patients in whom biopsies will be possible
Exclusion criteria
- Recipients of a liver from an hepatitis C virus positive (HCV+), human immunodeficiency virus positive (HIV+) or hepatitis B virus positive (HBV+) donor
- Patients with any severe coexisting disease or suffering any unstable medical condition or co-infected with HBV or HIV
- Patients with co-existing alcoholic disease who have not been abstinent for at least 6 months
- Transplanted for liver cancer exceeding a pre-defined size
- Pregnant or nursing women
Other protocol-defined inclusion/exclusion criteria may apply
Plan studiów
Jak projektuje się badanie?
Szczegóły projektu
- Główny cel: Zapobieganie
- Przydział: Randomizowane
- Model interwencyjny: Przydział równoległy
- Maskowanie: Brak (otwarta etykieta)
Broń i interwencje
Grupa uczestników / Arm |
Interwencja / Leczenie |
---|---|
Aktywny komparator: Cyclosporin A
The first administration of Cyclosporin A (CsA) was within the first 24 hours post-transplantation at an initial dose of 10-15mg/kg/day either orally, via a nasogastric (NG) tube or intravenously (i.v). Twice daily (b.i.d.) administration was maintained throughout the study period. During the study, the dose of CsA was adjusted, as necessary, to achieve and maintain the C2 or C0 blood CsA concentration within the target ranges. Before enrolling the first patient, each center chose the adjunct immunosuppressive (IS) regimen between:
The regimen selected by the center was to be given to all patients enrolled in the trial from this center. |
Initial dose of 10-15mg/kg/day either orally, via a nasogastric (NG) tube or intravenously (i.v.) within the first 24 hours post-transplantation.
Inne nazwy:
|
Aktywny komparator: Tacrolimus
Tacrolimus was administered within the first 24 hours post-transplantation at an initial dose of 0.1-0.15 mg/kg/day in 2 divided doses (twice daily at 12-hour interval) either orally or via a nasogastric (NG) tube or intravenously (i.v). Twice daily (b.i.d.) administration was maintained throughout study period. Throughout the study, the dose of tacrolimus was adjusted as necessary to achieve and maintain C0 tacrolimus concentrations within target ranges. Before enrolling the first patient, each center chose adjunct immunosuppressive (IS) regimen between:
The regimen selected by center was to be given to all patients enrolled in trial from this center. |
Tacrolimus was administered within the first 24 hours post-transplantation at an initial dose of 0.1-0.15
mg/kg/day in 2 divided doses either orally or via a nasogastric (NG) tube or intravenously (i.v).
|
Co mierzy badanie?
Podstawowe miary wyniku
Miara wyniku |
Opis środka |
Ramy czasowe |
---|---|---|
Number of Participants With Fibrosis Score 2 or Above [Ishak-Knodell Fibrosis Score (FS) ≥ 2] Within 1 Year Post-transplant
Ramy czasowe: 1 year post-transplant
|
Assessment of hepatic fibrosis was performed with liver biopsies at Day 1, Month 6, 12 and 24, read centrally by two independent pathologists blinded to treatment arm and time of biopsy.
Ishak-Knodell score was used to stage liver disease; 0= None; 1= Portal fibrosis (some); 2= Portal fibrosis (most); 3= Bridging fibrosis (few); 4= Bridging fibrosis (many); 5 = Incomplete cirrhosis; 6 = Cirrhosis.
Higher score indicates greater fibrosis.
Logistic regression on the presence of IK>=2 was applied based on central biopsy readings only.
|
1 year post-transplant
|
Miary wyników drugorzędnych
Miara wyniku |
Opis środka |
Ramy czasowe |
---|---|---|
Number of Participants With Combined Endpoint of Death or Graft Loss or Fibrosis Score (FS) ≥ 2
Ramy czasowe: 1 year post-transplant
|
The number of participants with combined end point of death or graft loss or presented with a Ishak-Knodell fibrosis score (FS) ≥2 was calculated.
Graft loss was considered to have occurred when allograft was presumed to be lost if a patient had liver retransplant or died.
Assessment of hepatic fibrosis was performed with liver biopsies read centrally.
Ishak-Knodell FS was used to stage liver disease; 0=none; 1=portal fibrosis (some); 2=portal fibrosis (most); 3=bridging fibrosis (few); 4=bridging fibrosis (many); 5=Incomplete cirrhosis; 6=cirrhosis.
Higher score indicates greater fibrosis.
|
1 year post-transplant
|
Number of Participants With Fibrosing Cholestatic Hepatitis
Ramy czasowe: 1 year post-transplantation
|
Fibrosing cholestatic hepatitis (FCH) is characterized by progressive jaundice with a rapid decline in liver function leading to liver failure, most often associated with markedly elevated viral levels detected in the bloodstream (e.g. more than 20 times pre-liver transplantation levels) and in the liver tissue as well.
The presence of FCH was reported based on the diagnosis given by the investigator.
|
1 year post-transplantation
|
Number of Participants With Death, Graft Loss, Death or Graft Loss, Graft Loss With Re-transplantation
Ramy czasowe: 1 year post-transplant
|
Graft loss was considered to have occurred when allograft was presumed to be lost if a patient had a liver re-transplant or died.
|
1 year post-transplant
|
Number of Participants With Treated Acute Rejection, Biopsy Proven Acute Rejection (BPAR), and Sub-clinical Rejection
Ramy czasowe: 1 year post-transplant
|
Treated acute rejection is defined as an acute rejection, clinically suspected, whether biopsy-proven or not, which has been treated and confirmed by the investigator according to the response to therapy.
BPAR was defined as a treated acute rejection confirmed by biopsy.
The local pathologist graded biopsies according to the Banff (1997) criteria.
A sub-clinical rejection was defined as a rejection identified by center driven biopsy, i.e. a biopsy performed routinely at some pre-defined time points after transplantation as per center practice in the absence of any clinical signs of rejection.
|
1 year post-transplant
|
Number of Participants With Combined Endpoint of Death or Graft Loss or Biopsy Proven Acute Rejection (BPAR)
Ramy czasowe: 1 year post-transplant
|
BPAR was defined as a treated acute rejection confirmed by biopsy.
The local pathologist graded biopsies according to the Banff (1997) criteria.
Graft loss was considered to have occurred when allograft was presumed to be lost if a patient had a liver re-transplant or died.
|
1 year post-transplant
|
Number of Participants With Death or Re-transplantation Due to Recurrence of Hepatitis C Cirrhosis
Ramy czasowe: 1 year post-transplant
|
Cirrhosis was resulted due to the recurrence of the hepatitis C virus infection in the transplanted liver.
|
1 year post-transplant
|
Number of Participants With Fibrosis Score 2 or Above [Ishak-Knodell Fibrosis Score (FS) ≥ 2] Within 1 Year Post-transplant (Intent to Treat Population)
Ramy czasowe: 1 year post-transplant
|
Assessment of hepatic fibrosis was performed with liver biopsies at Day 1, Month 6, 12 and 24, read centrally by two independent pathologists blinded to treatment arm and time of biopsy.
Ishak-Knodell score was used to stage liver disease; 0= None; 1= Portal fibrosis (some); 2= Portal fibrosis (most); 3= Bridging fibrosis (few); 4= Bridging fibrosis (many); 5 = Incomplete cirrhosis; 6 = Cirrhosis.
Higher score indicates greater fibrosis.
|
1 year post-transplant
|
Mean Value of Liver Function Tests at 1 Year Post-transplantation
Ramy czasowe: 1 year post-transplant
|
The mean value (in Units per liter, IU/L) of following tests were calculated at 1 year post-transplant:
|
1 year post-transplant
|
Log-transformed Hepatitis C Virus Ribonucleic Acid (HCV RNA) Values up to 1 Year Post Transplant
Ramy czasowe: Pre-transplant (Day 1), Day , Day 8, Day 29, Month 6 and 12 post- transplant
|
HCV RNA was measured (IU/µL)centrally pre-transplant (Day 1) and at 48 hours (Day 3), Day 8 and 29, Month 6 and 12 post-transplant and concomitantly to any additional biopsies performed.
|
Pre-transplant (Day 1), Day , Day 8, Day 29, Month 6 and 12 post- transplant
|
Percentage of Participants With an Increase of at Least 1 Stage in Fibrosis
Ramy czasowe: Between 1 and 2 years
|
Assessment of hepatic fibrosis was performed with liver biopsies at Day 1, Month 6, 12 and 24, read centrally by two independent pathologists blinded to treatment arm and time of biopsy.
Ishak-Knodell score was used to stage liver disease; 0= None; 1= Portal fibrosis (some); 2= Portal fibrosis (most); 3= Bridging fibrosis (few); 4= Bridging fibrosis (many); 5 = Incomplete cirrhosis; 6 = Cirrhosis.
Higher score indicates greater fibrosis.
An increase of at least 1 stage demonstrated a worsening of the disease, i.e. the transition from one score to the next higher one.
|
Between 1 and 2 years
|
Mean Fibrosis Score
Ramy czasowe: At 1and 2 years and its evolution over time
|
Assessment of hepatic fibrosis was performed with liver biopsies at Day 1, Month 6, 12 and 24, read centrally by two independent pathologists blinded to treatment arm and time of biopsy.
Ishak-Knodell score was used to stage liver disease; 0= None; 1= Portal fibrosis (some); 2= Portal fibrosis (most); 3= Bridging fibrosis (few); 4= Bridging fibrosis (many); 5 = Incomplete cirrhosis; 6 = Cirrhosis.
Higher score indicates greater fibrosis.
The mean score was equivalent to mean of IK at 1 and 2 years (evolution over time).
|
At 1and 2 years and its evolution over time
|
Współpracownicy i badacze
Sponsor
Daty zapisu na studia
Główne daty studiów
Rozpoczęcie studiów
Zakończenie podstawowe (Rzeczywisty)
Daty rejestracji na studia
Pierwszy przesłany
Pierwszy przesłany, który spełnia kryteria kontroli jakości
Pierwszy wysłany (Oszacować)
Aktualizacje rekordów badań
Ostatnia wysłana aktualizacja (Oszacować)
Ostatnia przesłana aktualizacja, która spełniała kryteria kontroli jakości
Ostatnia weryfikacja
Więcej informacji
Terminy związane z tym badaniem
Słowa kluczowe
Dodatkowe istotne warunki MeSH
- Choroby Układu Pokarmowego
- Procesy patologiczne
- Zakażenia wirusem RNA
- Choroby wirusowe
- Infekcje
- Infekcje przenoszone przez krew
- Choroby zakaźne
- Choroby wątroby
- Infekcje Flaviviridae
- Zapalenie wątroby, wirusowe, ludzkie
- Infekcje enterowirusowe
- Infekcje Picornaviridae
- Zwłóknienie
- Zapalenie wątroby
- Wirusowe Zapalenie Wątroby typu A
- Wirusowe zapalenie wątroby typu C
- Marskość wątroby
- Fizjologiczne skutki leków
- Molekularne mechanizmy działania farmakologicznego
- Środki przeciwinfekcyjne
- Inhibitory enzymów
- Środki przeciwreumatyczne
- Środki immunosupresyjne
- Czynniki immunologiczne
- Środki dermatologiczne
- Środki przeciwgrzybicze
- Inhibitory kalcyneuryny
- Takrolimus
- Cyklosporyna
- Cyklosporyny
Inne numery identyfikacyjne badania
- COLO400A2426
Te informacje zostały pobrane bezpośrednio ze strony internetowej clinicaltrials.gov bez żadnych zmian. Jeśli chcesz zmienić, usunąć lub zaktualizować dane swojego badania, skontaktuj się z register@clinicaltrials.gov. Gdy tylko zmiana zostanie wprowadzona na stronie clinicaltrials.gov, zostanie ona automatycznie zaktualizowana również na naszej stronie internetowej .
Badania kliniczne na Wirusowe zapalenie wątroby typu C
-
Dokuz Eylul UniversityEge UniversityZakończonyMMP9 | TIMP1 | MMP9-1562 C/T | TIMP1 372 T/CIndyk
-
Johann Wolfgang Goethe University HospitalZakończony
-
Meir Medical CenterZakończonyOpracowanie nowatorskiej techniki pomiaru współczynnika C/D z cyfrowych obrazów dysków optycznych stereo | Odtwarzalność pomiarów C/D wewnątrz obserwatora | Zmienność pomiarów C/D między obserwatorami
-
University College CorkDupont Applied BiosciencesRekrutacyjny
-
University Hospital, GrenobleClinical Investigation Centre for Innovative Technology NetworkZakończony
-
AronPharma Sp. z o. o.Medical University of Warsaw; Medical University of GdanskZakończonyBiodostępność witaminy CPolska
-
University Hospital, CaenZakończonyHemodynamic Monitoring, Positive Inotropic and Vasoactive Drugs During Cardiac Surgery (EMOA) (EMOA)C. Zabieg chirurgiczny; SercowyFrancja
-
University of Sao Paulo General HospitalInCor Heart Institute; Chinese Academy of Medical Sciences, Fuwai Hospital; Beneficência... i inni współpracownicyNieznanyC. Zabieg chirurgiczny; SercowyBrazylia
-
Hongwen JiZakończony
-
Seoul National University HospitalSMG-SNU Boramae Medical CenterZakończonyC. Zabieg chirurgiczny; SercowyRepublika Korei
Badania kliniczne na Cyclosporine A
-
Johnson & Johnson Vision Care, Inc.Zakończony
-
Johnson & Johnson Vision Care, Inc.ZakończonyZdarzenia związane z naciekiem rogówki | Zapalenie rogówkiStany Zjednoczone
-
Coopervision, Inc.Zakończony
-
Johnson & Johnson Vision Care, Inc.Zakończony
-
Coopervision, Inc.Zakończony
-
Bausch & Lomb IncorporatedZakończony
-
Johnson & Johnson Vision Care, Inc.University of ManchesterZakończonyAstygmatyzmZjednoczone Królestwo
-
University of OttawaZakończonyZaburzenie osobowości z pogranicza : zaburzenie typu borderline | Celowe samookaleczenie
-
Coopervision, Inc.ZakończonyAstygmatyzmZjednoczone Królestwo
-
Coopervision, Inc.ZakończonyAstygmatyzm | KrótkowzrocznośćMeksyk